Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis

BACKGROUND: Increases in lipid levels and cancers with tofacitinib prompted a trial of major adverse cardiovascular events (MACE) and cancers in patients with rheumatoid arthritis receiving tofacitinib as compared with a tumor necrosis factor (TNF) inhibitor. Several adverse events were more common with tofacitinib.

⚡ This is an original paraphrased summary — not copied from the abstract. Full paper available at the source link below.

• 1 METHODS: We conducted a randomized, open-label, noninferiority, postauthorization, safety end-point trial involving patients with active rheumatoid arthritis despite methotrexate treatment who were 50 years of age or older and had at least one additional cardiovascular risk factor.
• 2 Patients were randomly assigned in a 1:1:1 ratio to receive tofacitinib at a dose of 5 mg or 10 mg twice daily or a TNF inhibitor.
• 3 The coprimary end points were adjudicated MACE and cancers, excluding nonmelanoma skin cancer.

Understanding this could lead to better treatments, improved diagnostics, or a deeper grasp of how the human body works — benefiting patient care globally.

This summary is based on publicly available metadata and abstract. For the full research paper, visit the original source: